Copyright © 2011 Rosario Isasi and Bartha M. Knoppers. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. J. Hipp and A. Atala, “Sources of stem cells for regenerative medicine,” Stem Cell Reviews, vol. 4, no. 1, pp. 3–11, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
2. Geron, “Geron initiates clinical trial of human embryonic stem cell-based therapy,” October 2010.
3. Advanced Cell Technology, “Advanced cell technology receives FDA clearance for clinical trials using embryonic stem cells to treat age-related macular degeneration,” January 2011.
4. K. Takahashi, K. Tanabe, M. Ohnuki et al., “Induction of pluripotent stem cells from adult human fibroblasts by defined factors,” Cell, vol. 131, no. 5, pp. 861–872, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
5. G. Vogel, “Cellular reprogramming. New technique RiPS open stem cell field,” Science, vol. 330, no. 6001, p. 162, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
6. M. Csete, “Translational prospects for human induced pluripotent stem cells,” Regenerative Medicine, vol. 5, no. 4, pp. 509–519, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
7. R. McKernan, J. McNeish, and D. Smith, “Pharma's developing interest in stem cells,” Cell Stem Cell, vol. 6, no. 6, pp. 517–520, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
8. R. M. Isasi and B. M. Knoppers, “Governing stem cell banks and registries: emerging issues,” Stem Cell Research, vol. 3, no. 2-3, pp. 96–105, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
9. Organisation for Economic Co-operation and Development, The Bioeconomy to 2030: Designing A Policy Agenda, 2009.
10. A. Park, “Ten ideas changing the world right now: biobanks,” Times, 2009.
11. J. G. Day and G. N. Stacey, “Biobanking,” Molecular Biotechnology, vol. 40, no. 2, pp. 202–213, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
12. N. Nakatsuji, “Banking human pluripotent stem cell lines for clinical application?” Journal of Dental Research, vol. 89, no. 8, pp. 757–758, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
13. G. N. Stacey, “Consensus guidance for banking and supply of human embryonic stem cell lines for research purposes: the international stem cell banking initiative,” Stem Cell Reviews and Reports, vol. 5, no. 4, pp. 301–314, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
14. J. Borstlap, M. X. Luong, H. M. Rooke et al., “International stem cell registries,” In Vitro Cellular and Developmental Biology, vol. 46, no. 3-4, pp. 242–246, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
15. L. Noel, “Who guiding principles on human cell, tissue and organ transplantation,” Transplantation, vol. 90, no. 3, pp. 229–233, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
16. The European Commission, “Commission directive 2006/17/EC of 8 February 2006 implementing directive 2004/23/EC of the European parliament and of the Council as regards certain technical requirements for the donation, procurement and testing of human tissues and cells,” Official Journal of the European Union, 2006.
17. The European Commission, “Commission directive 2006/86/EC of 24 October 2006 implementing directive 2004/23/EC of the European parliament and of the Council as regards traceability requirements, notification of serious adverse reactions and events and certain technical requirements for the coding, processing, preservation, storage and distribution of human tissues and cells,” Official Journal of the European Union, 2006.
18. N. Nakatsuji, “Banking human pluripotent stem cell lines for clinical application?” Journal of Dental Research, vol. 89, no. 8, pp. 757–758, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
19. K. D. Sermon, C. Simon, P. Braude, S. Viville, J. Borstlap, and A. Veiga, “Creation of a registry for human embryonic stem cells carrying an inherited defect: joint collaboration between ESHRE and hESCreg,” Human Reproduction, vol. 24, no. 7, pp. 1556–1560, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
20. Reproductive Genetics Institute, Stem Cell Bank, http://www.reproductivegenetics.com/stem_cell_bank.html.
21. WiCell Research Institute, WISC Bank, http://www.wicell.org/index.php?option=com_oscommerce&Itemid=272.
22. Organization for economic co-operation and development (OECD), “Creation and governance of human genetic research databases,” 2006.
23. G. N. Stacey, “Sourcing human embryonic stem cell lines,” in Human Embryonic Stem Cells: The Practical Handbook, S. Sullivan, C. A. Cowan, and K. Eggan, Eds., John Wiley & Sons, New York, NY, USA, 2007.
24. B. M. Knoppers and R. Isasi, “Stem cell banking: between traceability and identifiability,” Genome Medicine, vol. 2, no. 10, p. 73, 2010. View at Publisher · View at Google Scholar · View at PubMed
25. B. M. Knoppers and M. H. Abdul-Rahman, “Health privacy in genetic research,” Politics and the Life Sciences, vol. 28, no. 2, pp. 99–101, 2009. View at Publisher · View at Google Scholar · View at Scopus
26. B. M. Knoppers, R. Isasi, N. Benvenisty, et al., “Publishing SNP genotypes of human embryonic stem cell lines (hESC): a policy statement,” Stem Cell Reviews and Reports, vol. 7, no. 3, pp. 482–484, 2011. View at Publisher · View at Google Scholar · View at PubMed
27. R. M. Isasi and B. M. Knoppers, “Beyond the permissibility of embryonic and stem cell research: substantive requirements and procedural safeguards,” Human Reproduction, vol. 21, no. 10, pp. 2474–2481, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
28. V. Ozdemir and B. M. Knoppers, “One size does not fit all: toward “upstream ethics”?” American Journal of Bioethics, vol. 10, no. 6, pp. 42–44, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
29. B. Lo and L. Parham, “Ethical issues in stem cell research,” Endocrine Reviews, vol. 30, no. 3, pp. 204–213, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
30. A. Zarzeczny, C. Scott, I. Hyun et al., “iPS cells: mapping the policy issues,” Cell, vol. 139, no. 6, pp. 1032–1037, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
31. C. Hewitt, “Uses and abuses of the concept of governance,” International Social Science Journal, vol. 50, no. 155, p. 105, 2002.
32. M. Deschênes and C. Sallée, “Accountability in population biobanking: comparative approaches,” Journal of Law, Medicine and Ethics, vol. 33, no. 1, pp. 40–53, 2005. View at Scopus
33. A. Cambon-Thomsen, E. Rial-Sebbag, and B. M. Knoppers, “Trends in ethical and legal frameworks for the use of human biobanks,” European Respiratory Journal, vol. 30, no. 2, pp. 373–382, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
34. R. M. Isasi, “Policy interoperability in stem cell research: demystifying harmonization,” Stem Cell Reviews and Reports, vol. 5, no. 2, pp. 108–115, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
35. P. P. O'Rourke, M. Abelman, and K. G. Heffernan, “Centralized banks for human embryonic stem cells: a worthwhile challenge,” Cell Stem Cell, vol. 2, no. 4, pp. 307–312, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
36. European Group of Ethics in Science and New Technologies to the European Commission, “Recommendations on the ethical review of HESC FP7 research projects,” Opinion, no. 22, 2007.
37. J. Sugarman and A. W. Siegel, “Research ethics: when embryonic stem cell lines fail to meet consent standards,” Science, vol. 322, no. 5900, p. 379, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
38. K. Aalto-Setälä, B. R. Conklin, and B. Lo, “Obtaining consent for future research with induced pluripotent cells: opportunities and challenges.,” PLoS Biology, vol. 7, no. 2, p. e42, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
39. B. Lo, L. Parham, A. Alvarez-Buylla et al., “Cloning mice and men: prohibiting the use of iPS cells for human reproductive cloning,” Cell Stem Cell, vol. 6, no. 1, pp. 16–20, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
40. R. M. Isasi, “Policy interoperability in stem cell research: demystifying harmonization,” Stem Cell Reviews and Reports, vol. 5, no. 2, pp. 108–115, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
41. J. Menikoff, “The paradoxical problem with multiple-IRB review,” New England Journal of Medicine, vol. 363, no. 17, pp. 1591–1593, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
42. The Interagency Advisory Panel on Research Ethics, “Tri-council policy statement: ethical conduct for research involving humans,” 2010.
43. The Academy of Medical Sciences, “A new pathway for the regulation and governance of health research,” 2011.
44. The Hinxton Group, “Statement on policies and practices governing data and material sharing and intellectual property in stem cell science,” 2010.
45. J. Borstlap, M. X. Luong, H. M. Rooke et al., “International stem cell registries,” In Vitro Cellular and Developmental Biology, vol. 46, no. 3-4, pp. 242–246, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
46. J. M. Crook, D. Hei, and G. Stacey, “The international stem cell banking initiative (ISCBI): raising standards to bank on,” In Vitro Cellular and Developmental Biology, vol. 46, no. 3-4, pp. 169–172, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
47. B. J. von Tigerstrom, “The challenges of regulating stem cell-based products,” Trends in Biotechnology, vol. 26, no. 12, pp. 653–658, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
48. T. Caulfield, A. Zarzeczny, J. McCormick et al., “The stem cell research environment: a patchwork of patchworks,” Stem Cell Reviews and Reports, vol. 5, no. 2, pp. 82–88, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
49. H. Chen, “Stem cell governance in China: from bench to bedside?” New Genetics and Society, vol. 28, no. 3, pp. 267–282, 2009. View at Publisher · View at Google Scholar · View at Scopus
50. E. Rowley and P. Martin, “Barriers to commercialisation and utilisation of regenerative medicine in the UK,” Institute for Science and Society, University of Nottingham, Nottingham, UK, 2009.
51. A. Trounson, E. Baum, D. Gibbons, and P. Tekamp-Olson, “Developing a case study model for successful translation of stem cell therapies,” Cell Stem Cell, vol. 6, no. 6, pp. 513–516, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
52. J. T. Daniels, G. A. Secker, A. J. Shortt, S. J. Tuft, and S. Seetharaman, “Stem cell therapy delivery: treading the regulatory tightrope,” Regenerative Medicine, vol. 1, no. 5, pp. 715–719, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
53. A. Trounson, R. G. Thakar, G. Lomax, and D. Gibbons, “Clinical trials for stem cell therapies,” BioMed Central, vol. 9, no. 52, 2011. View at Publisher · View at Google Scholar · View at PubMed
54. J. F. Fox, “Human iPSC and ESC translation potential debated,” Nature Biotechnology, vol. 29, pp. 375–376, 2011. View at Publisher · View at Google Scholar · View at PubMed
55. D. G. Halme and D. A. Kessler, “FDA regulation of stem-cell-based therapies,” New England Journal of Medicine, vol. 355, no. 16, pp. 1730–1735, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
56. J. L. Fox, “FDA scrutinizes human stem cell therapies,” Nature Biotechnology, vol. 26, no. 6, pp. 598–599, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
57. D. W. Fink, “FDA regulation of stem cell-based products,” Science, vol. 324, no. 5935, pp. 1662–1663, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
58. E. C. Hayden, “Stem cells: the growing pains of pluripotency,” Nature, vol. 473, no. 7347, pp. 272–274, 2011. View at Publisher · View at Google Scholar · View at PubMed
59. N. Amariglio, A. Hirshberg, B. W. Scheithauer et al., “Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient,” PLoS Medicine, vol. 6, no. 2, Article ID e1000029, 2009. View at Publisher · View at Google Scholar · View at PubMed
60. D. Lau, U. Ogbogu, B. Taylor, T. Stafinski, D. Menon, and T. Caulfield, “Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine,” Cell Stem Cell, vol. 3, no. 6, pp. 591–594, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
61. S. Kiatpongsan and D. Sipp, “Offshore stem cell treatments,” Nature Reports Stem Cells. In press. View at Publisher · View at Google Scholar
62. O. Lindvall and L. Hyun, “Medical innovation versus stem cell tourism,” Science, vol. 324, no. 5935, pp. 1664–1665, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
63. C. A. Herberts, M. S. G. Kwa, and H. P. H. Hermsen, “Risk factors in the development of stem cell therapy,” Journal of Translational Medicine, vol. 9, no. 29, 2011. View at Publisher · View at Google Scholar · View at PubMed
64. K. Martell, A. Trounson, and E. Baum, “Stem cell therapies in clinical trials: workshop on best practices and the need for harmonization,” Cell Stem Cell, vol. 7, no. 4, pp. 451–454, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
65. L. Brévignon-Dodin and F. Livesey, “Regulation of tissue-engineered products in the European Union: where are we heading?” Regenerative Medicine, vol. 1, no. 5, pp. 709–714, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
66. L. Brévignon-Dodin and P. Singh, “ATMP in practice: towards a new industry landscape in tissue engineering,” Journal of Commercial Biotechnology, vol. 15, no. 1, pp. 59–65, 2009. View at Publisher · View at Google Scholar · View at Scopus
67. N. Stafford, “Germany tightens law on stem cell treatments,” British Medical Journal, vol. 339, p. b2967, 2009. View at Publisher · View at Google Scholar · View at Scopus
68. D. McMahon and H. Thorsteinsdottir, “Regulations are needed for stem cell tourism: insights from China,” American Journal of Bioethics, vol. 10, no. 5, pp. 34–36, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
69. European Union, “Regulation (EC) No 1394 of the European parliament and of the Council on advanced therapy medicinal products and amending directive 2001/83/EC and regulation (EC) No 726/2004,” O.J. L 324/121, 2007.
70. C. K. Schneider and P. Celis, “Challenges with advanced therapy medicinal products and how to meet them,” Nature Reviews Drug Discovery, vol. 9, no. 3, pp. 195–201, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
71. Therapeutic Goods Administration (TGA), “Australia (2009) biologicals framework implementation,” http://www.tga.gov.au/industry/biologicals-framework.htm.
72. Canadian Standards Association, Cells, Tissues, and Organs for Transplantation: General Requirements (Draft Standard-Z900.1), 2nd edition, 2010.
73. Food and Drug Administration (FDA), “Briefing document: CTGTAG Meeting #45: cellular therapies derived from human embryonic stem cells—considerations for pre-clinical safety testing and patient monitoring,” April 2008.
74. A. Trounson, E. Baum, D. Gibbons, and P. Tekamp-Olson, “Developing a case study model for successful translation of stem cell therapies,” Cell Stem Cell, vol. 6, no. 6, pp. 513–516, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
75. J. M. Crook, D. Hei, and G. Stacey, “The international stem cell banking initiative (ISCBI): raising standards to bank on,” In Vitro Cellular and Developmental Biology, vol. 46, no. 3-4, pp. 169–172, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
76. E. Rowley and P. Martin, “Barriers to the commercialization & utilisation of regenerative medicine in the UK,” Institute for Science and Society, University of Nottingham, Nottingham, UK, 2009.
77. J. T. Daniels, G. A. Secker, A. J. Shortt, S. J. Tuft, and S. Seetharaman, “Stem cell therapy delivery: treading the regulatory tightrope,” Regenerative Medicine, vol. 1, no. 5, pp. 715–719, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
78. International Cancer Genome Consortium, “E.1. informed consent, access and ethical oversight,” in Proceedings of the E-Consortium Policies and Guidelines, 2008.
79. K. Martell, A. Trounson, and E. Baum, “Stem cell therapies in clinical trials: workshop on best practices and the need for harmonization,” Cell Stem Cell, vol. 7, no. 4, pp. 451–454, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
80. N. Cuende and A. Izeta, “Clinical translation of stem cell therapies: a bridgeable gap,” Cell Stem Cell, vol. 6, no. 6, pp. 508–512, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
81. J. Morris and S. Coles, “Will the FDA kill adult stem cell medicine?” Humanity+ Magazine, 2009.
82. D. Cyranoski, “Korean deaths spark inquiry,” Nature, vol. 468, no. 7323, p. 485, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
83. A. Nagy and S. E. Quaggin, “Stem cell therapy for the kidney: a cautionary tale,” Journal of the American Society of Nephrology, vol. 21, no. 7, pp. 1070–1072, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
84. B. M. Simon, C. E. Murdoch, and C. T. Scott, “Pluripotent patents make prime time: an analysis of the emerging landscape,” Nature Biotechnology, vol. 28, no. 6, pp. 557–559, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
85. M. Eisenstein, “Up for grabs,” Nature Biotechnology, vol. 28, no. 6, pp. 544–546, 2010. View at Publisher · View at Google Scholar · View at PubMed
86. I. MacLeod, “US biotech firm seeks Canadian stem cell patent,” The Gazette, 2010, Postemedia News.
87. E. Dolgin, “Patents draw new lines in the battle to commercialize stem cells,” Nature Medicine, vol. 16, no. 3, p. 246, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
88. D. Sipp, “Gold standards in the diamond age: the commodification of pluripotency,” Cell Stem Cell, vol. 5, no. 4, pp. 360–363, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
89. Mainichi Newspaper Japan, “Kyoto University gains exclusive rights to iPS-related technology, avoid patent spat,” February 2011.
90. A. B. Parson, “Stem cell biotech: seeking a piece of the action,” Cell, vol. 132, no. 4, pp. 511–513, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
91. T. N. McAllister, N. Dusserre, M. Maruszewski, and N. L'Heureux, “Cell-based therapeutics from an economic perspective: primed for a commercial success or a research sinkhole?” Regenerative Medicine, vol. 3, no. 6, pp. 925–937, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
92. D. Smith, “Commercialization challenges associated with induced pluripotent stem cell-based products,” Regenerative Medicine, vol. 5, no. 4, pp. 593–603, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
93. A. Courtney, P. De Sousa, C. George, G. Laurie, and J. Tait, “Balancing open source stem cell science with commercialization,” Nature Biotechnology, vol. 29, no. 2, pp. 115–116, 2011. View at Publisher · View at Google Scholar · View at PubMed
94. D. J. H. Mathews, G. D. Graff, K. Saha, and D. E. Winickoff, “Access to stem cells and data: persons, property rights, and scientific progress,” Science, vol. 331, no. 6018, pp. 725–727, 2011. View at Publisher · View at Google Scholar · View at PubMed
95. C. C. George, “Open access and the regulation of commercialisation of human stem cell lines in the UKSCB,” SCRIPTed, vol. 7, no. 2, 2010. View at Publisher · View at Google Scholar
96. Y. Joly, T. Caulfield, B. M. Knoppers, E. Harmsen, and T. Pastinen, “Points to consider: the commercialization of genomic research in Canada,” Health Care Policy, vol. 6, no. 2, pp. 24–32, 2010.
97. A. Plomer and P. Torremans, Embryonic Stem Cell Patents: European Law and Ethics, Oxford University Press, Oxford, UK, 2009.
98. European Court of Justice. Case C-34/10, Oliver Brustle vs. Greenpeace eV. Opinion of Advocate General, March 2011.
99. B. M. Knoppers and R. Isasi, “Stem cell banking: between traceability and identifiability,” Genome Medicine, vol. 2, no. 10, 2010. View at Publisher · View at Google Scholar · View at PubMed
100. M. Baker, “Caution and hope for the stem cell industry,” Nature Reports Stem Cells. In press. View at Publisher · View at Google Scholar
101. T. N. McAllister, N. Dusserre, M. Maruszewski, and N. L'Heureux, “Cell-based therapeutics from an economic perspective: primed for a commercial success or a research sinkhole?” Regenerative Medicine, vol. 3, no. 6, pp. 925–937, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
102. E. Zika, D. Paci, A. Braun et al., “A European survey on biobanks: trends and issues,” Public Health Genomics, vol. 14, no. 2, pp. 96–103, 2011, http://www.hinxtongroup.org/Consensus_HG10_FINAL.pdf. View at Publisher · View at Google Scholar · View at PubMed
103. S. Fortin, S. Pathmasiri, R. Grintuch, and M. Deschênes, ““Access arrangements” for biobanks: a fine line between facilitating and hindering collaboration,” Public Health Genomics, vol. 14, no. 2, pp. 104–114, 2011. View at Publisher · View at Google Scholar · View at PubMed